Brief: Tempest Receives Orphan Drug Designation From U.S. FDA For Amezalpat
06/01/2025 13:29
Jan 6 (Reuters) - Tempest Therapeutics Inc TPST.O :
* TEMPEST RECEIVES ORPHAN DRUG DESIGNATION FROM THE U.S.
FOOD AND
DRUG ADMINISTRATION FOR AMEZALPAT TO TREAT PATIENTS WITH
HEPATOCELLULAR CARCINOMA (HCC)
Source text: urn:newsml:reuters.com:*:nGNX9Dyhdg
Further company coverage: TPST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T